Article · 5 Oct 2026
Research articlePublished 9 Jun 2022
Assessment of Bioequivalence of Two Tramadol Hydrochloride 100 mg Extended-Release Tablet Formulations in Healthy Thai Volunteer
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Tramadol hydrochloride 100 mg extended-release tablets is available as the registered trademark, Tramal® retard in Thailand to reduce a dosing frequency for the treatment of moderate to severe pain. The Government Pharmaceutical Organization had developed the generic tramadol hydrochloride 100 mg extended-release tablets (Tramadol retard GPO®) to serve as an alternative product which is more accessible and affordable without compromising quality. Two separate single-dose bioequivalence studies under fasting and fed conditions and one multiple-dose bioequivalence study under fasting conditions were conducted in healthy Thai volunteers using a comparative randomized, two-way crossover, open-label design to demonstrate the equivalence in bio pharmaceutics quality between two tramadol formulations. Tramadol plasma concentrations were quantified using a validated liquid chromatography-mass spectrometry method. The 90% confidence intervals for the geometric least squares mean ratios of log-transformed AUC0-tlast, AUC0-∞ and Cmax for the single-dose studies and log-transformed AUC 0-τ,ss, Cτ,ss and C max,ssfor the multiple-dose study were within 80.00%-125.00% of bioequivalence criteria. The analysis of variance did not show significant effect of the formulation on the primary pharmacokinetic parameters. Wilcoxon signed-rank test also showed no significant difference in median tmax between two formulations in any studies. Bioequivalence between the test and reference products was concluded based on insignificant difference in terms of rate and extent of absorption.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Bioequivalence & Bioavailability.
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Bioequivalence & Bioavailability
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Vipada Khaowroongrueng”
- BylineArticles whose byline prints “Wiwat Supasena”
- BylineArticles whose byline prints “Polsak Teerawonganan”
- BylineArticles whose byline prints “Ekawan Yoosakul”
- BylineArticles whose byline prints “Lalinthip Saeaue”
- BylineArticles whose byline prints “Busarat Karachot”
- BylineArticles whose byline prints “Isariya Techatanawat”
- BylineArticles whose byline prints “Archawin Rojanawiwat”